Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS
Positive results from ianalumab pivotal Phase III trial in ITP patients previously…
PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer
Basel, October 19, 2025 – Novartis today presents new Pluvictoâ„¢ (lutetium (177Lu)…